Refine
Has Fulltext
- yes (231)
Is part of the Bibliography
- yes (231)
Year of publication
Document Type
- Journal article (214)
- Conference Proceeding (11)
- Doctoral Thesis (4)
- Other (2)
Language
- English (231) (remove)
Keywords
- Chirurgie (26)
- Medizin (9)
- inflammation (9)
- Immunbiologie (8)
- colorectal cancer (8)
- obesity (8)
- cytokines (6)
- Immunobiologie (4)
- Roux-en-Y gastric bypass surgery (4)
- bariatric surgery (4)
- inflammatory bowel disease (4)
- Ureaplasma parvum (3)
- anastomotic leakage (3)
- chemotherapy (3)
- evidence-based medicine (3)
- guidelines (3)
- incisional hernia (3)
- indication for surgery (3)
- intestinal epithelial barrier (3)
- laparoscopic ventral hernia repair (3)
- liraglutide (3)
- open abdomen (3)
- perioperative management (3)
- sepsis (3)
- 5-Fluorouracil (2)
- Aspergillus (2)
- COVID-19 (2)
- CRC (2)
- Caco2 cells (2)
- Cancer (2)
- Crohn's disease (2)
- DNA damage (2)
- Fn14 (2)
- Germany (2)
- Krebs (2)
- Krebs <Medizin> (2)
- Langerhans-Inseln (2)
- MYC (2)
- NAFLD (2)
- NFκB (2)
- Rectal cancer (2)
- SARS-CoV-2 (2)
- Surgery (2)
- TWEAK (2)
- Transplantation (2)
- Ureaplasma urealyticum (2)
- adaptive immunity (2)
- adrenocortical carcinoma (2)
- agonistic antibodies (2)
- animal model (2)
- anticoagulation (2)
- antimicrobial stewardship (2)
- atrial fibrillation (2)
- biomarker (2)
- bridging (2)
- cancer (2)
- case report (2)
- cell death (2)
- colon cancer (2)
- complication (2)
- dendritic cells (2)
- desmosome (2)
- endoluminal (2)
- enzyme activation (2)
- enzyme inhibitors (2)
- extracorporeal membrane oxygenation (2)
- gastric bypass (2)
- gastric cancer (2)
- giant ventral hernia (2)
- gut barrier (2)
- ileocecal resection (2)
- immunoassay (2)
- ischemia (2)
- islets of Langerhans (2)
- laparostomy (2)
- malignant melanoma (2)
- meta-analysis (2)
- metastasis (2)
- microbial spectrum (2)
- mortality (2)
- negative pressure (2)
- oxaliplatin (2)
- pancreatic cancer (2)
- parastomal hernia (2)
- pediatric (2)
- peptide tyrosine tyrosine (PYY) (2)
- peritoneal carcinomatosis (2)
- phosphodiesterase (2)
- postoperative bleeding (2)
- preterm infants (2)
- primary ventral hernia (2)
- rat (2)
- rectum (2)
- skin (2)
- surgery (2)
- surgical therapy (2)
- swine (2)
- synthetic mesh (2)
- therapy (2)
- thromboembolism (2)
- translational research (2)
- treatment (2)
- umbilical hernia (2)
- vacuum conditioning (2)
- vacuum-assisted closure (2)
- ventral hernia (2)
- 15-Deoxyspergualin (1)
- 1st-line treatment (1)
- 5-fluorouracil (1)
- 6-percent hydroxyethyl starch (1)
- AAA (1)
- ALCL (1)
- Activation (1)
- Adrenocortical Carcinoma (1)
- Allergie (1)
- Allopeptidb (1)
- Allotransplantatabstossung (1)
- Apoptosis (1)
- Attentional performance (1)
- Autologous (1)
- BM (1)
- Barrett-Ösophagus (1)
- Bauchspeicheldrüsenkrebs (1)
- Beta-catenin (1)
- Blood–brain barrier (1)
- Brain μ-opioid receptors (1)
- C-MYC (1)
- CA19-9 (1)
- CASP (1)
- CCR7 (1)
- CD62L (1)
- CIP2A (1)
- CNS integrity (1)
- COVID-19 pandemic (1)
- CT angiography (1)
- CX3CL1 (1)
- CX5461 (1)
- CXCL13 (1)
- Cancer immunotherapy (1)
- Carcinoma cells (1)
- Carcinomatosis (1)
- Central venous access (1)
- Central venous-pressure (1)
- Chemotherapeutic resistance (1)
- Class II antigen blockade (1)
- Claudin2 (1)
- Cognitive (1)
- Coronary artery bypass graft (1)
- Coronavirus Disease 2019 (1)
- Critically-ill patients (1)
- Crohn’s Disease (1)
- Crohn’s disease (1)
- Cryolesion (1)
- Cushing (1)
- DNA repair (1)
- Danish hernia database (1)
- Diabetes (1)
- Dickdarmkrebs (1)
- Dsg2 (1)
- Dünndarm (1)
- EDS (1)
- EHS classification (1)
- ERK (1)
- Ehlers-Danlos syndrome (1)
- Elective cesarean-section (1)
- Electrical impedance tomography (1)
- EndoVAC and small bowel (1)
- Epstein-Barr virus (1)
- Experimental brain trauma (1)
- Expression (1)
- Extra-anatomical (1)
- FWGE (1)
- Fascia transversalis (1)
- FcγR (1)
- Femoral vein (1)
- Fibroblasts (1)
- Fluorouracil (1)
- Foxp3 (1)
- GDNF5 (1)
- GIST (1)
- GLP-1 (1)
- General anaesthesia (1)
- Groin infection (1)
- Growth-factor receptor (1)
- Göttingen (1)
- HBMEC (1)
- Heterotransplantation (1)
- Hickman catheter (1)
- High-fat diet (1)
- Hypertonic saline 7.5-percent (1)
- IL-6 (1)
- IVF-methods (1)
- Ileal conduit (1)
- Ileum-Conduit (1)
- Immunologie (1)
- Immunosenescence (1)
- Immunotherapy (1)
- Improved survival (1)
- In vitro models (1)
- Inhibition (1)
- Invasion (1)
- Inzisionale Hernie (1)
- Inzisionalhernie (1)
- KIT (1)
- Kono-S anastomosis (1)
- LAMN (1)
- LND (1)
- LNE (1)
- Lactated ringers solution (1)
- Laparoscopy (1)
- Leistenhernie (1)
- Leptin (1)
- Lernkurve (1)
- Linea alba (1)
- Low-fat diet (1)
- LyP (1)
- Lymph nodes (1)
- MAPK pathway (1)
- MAPK signaling cascades (1)
- MHC I (1)
- MHC Klasse II (1)
- MHC-Klass I (1)
- MITF (1)
- MIZ1 (1)
- MPFL (1)
- MRI (1)
- MTL30 (1)
- Major abdominal surgery (1)
- Makrophage (1)
- Mammalian target (1)
- Matrix (1)
- Melanom (1)
- Melanoma (1)
- Merkel cell carcinoma (1)
- Merkelzellkarzinom (1)
- Mesh Augmentation (1)
- Metastatic breast cancer (1)
- Mice (1)
- Minimalinvasiv (1)
- Minimalinvasive Leistenhernienversorgung (1)
- Minimally invasive surgery (1)
- Minischwein (1)
- Modifizierte Sugarbaker-Technik (1)
- Monoclonal antibody (1)
- Multicenter randomized-trial (1)
- NASH (1)
- NPWT (1)
- Niere (1)
- Obturator bypass (1)
- Oncology (1)
- Organoids (1)
- Organtransplantation (1)
- P-glycoprotein (1)
- PCI (1)
- PCR (1)
- PDE (1)
- PDE4-I (1)
- PDGF (1)
- PET (1)
- PET imaging (1)
- PI-3-kinase (1)
- PI3K/Akt/mTOR (1)
- PLAG1 rearrangement (1)
- POEM (1)
- PYY3-36 (1)
- Parastomale Hernie (1)
- Pathway (1)
- Pauli procedure (1)
- Pauli-Verfahren (1)
- Pediatric malignancy (1)
- Peptidanaloge (1)
- Port (1)
- Posteriore Komponentenseparation (1)
- Postoperative complications (1)
- Predict fluid responsiveness (1)
- Primary hyperparathyroidism (pHPT) (1)
- Pulmonary function tests (1)
- Puls-pressure variation (1)
- RET6 (1)
- RNAPOL1 (1)
- RYGB (1)
- Radical prostatectomy (1)
- Radiochemotherapy (1)
- Randomized controlled-trial (1)
- Ratte (1)
- Regulatorischer T-Lymphozyt (1)
- Regulatory T cells (1)
- Retromuskuläres Netz (1)
- Retrorektus Netz (1)
- Robotik (1)
- Roux-en-Y gastric bypass (1)
- SSI (1)
- ST18 (1)
- Secondary traumatic brain damage (1)
- Serom (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- T cell receptors (1)
- T cells (1)
- TCR (1)
- TCR signaling cascade (1)
- TEER (1)
- TLR2 (1)
- TLR4 (1)
- TLR7 (1)
- TLR8 (1)
- TLR9 (1)
- TME (1)
- TNF (1)
- TNF receptor superfamily (1)
- TREC (1)
- Telomere (1)
- Thrombosis (1)
- Time interval (1)
- Tissue (1)
- Toll-like receptor signaling (1)
- Toll-like-Rezeptoren (1)
- Trichternetz (IPST) (1)
- Tumorerkrankungen (1)
- Umbilikalhernie (1)
- Up-regulation (1)
- V. saphena magna (1)
- VAC (1)
- VLBW (1)
- Ventrale Hernie (1)
- Y-gastric bypass (1)
- ZfKD (1)
- Zucker fatty fa/fa rats (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [18F]FDG-PET-CT (1)
- [99mTc]-Sestamibi scan (1)
- abdominal compartment syndrome (1)
- abdominal lymph node metastases (1)
- abdominal surgery (1)
- abdominal trauma (1)
- abdominal wall hernia (1)
- abdominal wall surgery (1)
- accumulation (1)
- achalasia (1)
- acute (1)
- acute appendicitis (1)
- acute kidney injury (1)
- acute liver failure (1)
- acute respiratory distress syndrome (1)
- adipose-derived stromal/stem cells (ASCs) (1)
- adiposity (1)
- adjuvant (1)
- adrenal cancer (1)
- adrenal surgery (1)
- adrenal tumors (1)
- adrenalectomia (1)
- adrenocortical (1)
- adrenocortical adenocarcinoma (1)
- allograft rejection (1)
- allopeptide (1)
- alternative splicing (1)
- alveolar epithelium (1)
- anal atresia (1)
- anaplastic large cell lymphoma (1)
- anastomosis (1)
- anastomotic leak (1)
- anorectal abscess (1)
- anorectal angl (1)
- anorectal malformation (1)
- anti-tumor effects (1)
- antibiotic prescribing quality (1)
- antibiotic prescription behavior (1)
- antibiotic resistance (1)
- antibiotics (1)
- antithrombotic therapy (1)
- appendectomy (1)
- appendicitis (1)
- appendix (1)
- assisted reproductive techniques (1)
- autophagy (1)
- barrier models (1)
- benzoquinone (1)
- beta cells (1)
- biliopancreatic diversion (1)
- biological models (1)
- birth defects (1)
- bladder (1)
- blood (1)
- blood samples (1)
- blood-nerve barrier (1)
- blood–brain barrier (1)
- body fat (1)
- body mass index (BMI; kg/m\(^2\)) (1)
- body weight (1)
- bone marrow (1)
- brain metastases (1)
- brain plasticity (1)
- breast cancer (1)
- bronchopulmonary dysplasia (1)
- brown adipose tissue (1)
- bullae (1)
- burst abdomen (1)
- caco-2 cells (1)
- cadaver multiorgan preservation (1)
- caloric-restriction (1)
- cancer cells (1)
- cancer diagnosis (1)
- cancer risk (1)
- cancer treatment (1)
- cancers and neoplasms (1)
- capture (1)
- carcinogenesis (1)
- carcinoma metastases to pancreas (1)
- carcinomas (1)
- cardiogenic (1)
- catheterization (1)
- catheters (1)
- cell cycle and cell division (1)
- cellular senescence (1)
- cerebEND (1)
- cerebral metastases (1)
- chemistry (1)
- chemokine receptor (1)
- children (1)
- children born (1)
- cholestasis (1)
- chylomicron (1)
- colloids (1)
- colon (1)
- colon carcinoma cells (1)
- colon resection (1)
- colorectal carcinoma (1)
- comet assay (1)
- complications (1)
- computed tomography angiography (CTA) (1)
- congenital malformations (1)
- continuous extracorporeal femoral perfusion model (1)
- conventional laparoscopic appendectomy (1)
- cord blood (1)
- cost-effectiveness (1)
- cotransporter SGLT1 (1)
- creatinine (1)
- curative resection (1)
- cytostatic (1)
- cytotoxicity (1)
- dass II antigen blockade (1)
- deconstruction into key steps (1)
- definition (1)
- dendritische Zellen (1)
- descriptive epidemiology (1)
- desmoglein (1)
- dexamethasone (1)
- diabetes (1)
- diagnosis (1)
- diagnostics (1)
- digital subtraction angiography (DSA) (1)
- discharge definition (1)
- drug-eluting beads (1)
- dual-room whole-body CT (1)
- duodenal jejunal bypass (1)
- duodenal perforation (1)
- duodenal trauma (1)
- elective surgery (1)
- endoscopic (1)
- endoscopic full thickness resection (eFTR) (1)
- endoscopic groin hernia repair (1)
- endosponge (1)
- endotoxemia (1)
- endovascular repair (1)
- energy homeostasis (1)
- enteric glial cells (1)
- enteric nervous system (1)
- enteroids (1)
- ephitelial cells (1)
- epidemiology (1)
- epidural block (1)
- epigastric hernia (1)
- epithelial cells (1)
- epithelium (1)
- erratum (1)
- esophageal perforation (1)
- expenditure (1)
- experimental models of disease (1)
- experimental therapy (1)
- extremity trauma (1)
- fascial closure (1)
- fat absorption (1)
- fat appetite (1)
- fatty liver (1)
- femoral arteries (1)
- femoral hernia (1)
- fish bone (1)
- fistulizing Crohn’s Disease (1)
- flow cytometry (1)
- focused surgical approach (1)
- folinic acid (1)
- food intake (1)
- foreign body ingestion (1)
- fracture-associated vascular damage (1)
- full-thickness resection device (FTRD) (1)
- funnel mesh (IPST) (1)
- gastric-bypass surgery (1)
- gastrointestinal cancer (1)
- gastrointestinal infections (1)
- gastrointestinal perforation (1)
- gastrointestinal tract (1)
- gemcitabine (1)
- gene regulation (1)
- generation (1)
- geriatric (1)
- germline mutation (1)
- glucagon like peptide-1 (1)
- glucocorticoid receptor (1)
- glucose homeostasis (1)
- glucose metabolism (1)
- glucose starvation (1)
- groin hernia (1)
- growth differentiation factor 15 (1)
- gut hormones (1)
- hematology (1)
- hemorrhagic (1)
- henoch-schönlein purpura (1)
- hepatic resection (1)
- hepatocellular carcinoma (1)
- hernia (1)
- hernia defect (1)
- hernia repair material (1)
- histologic diversity (1)
- histopathology (1)
- human biomonitoring (1)
- human cancer (1)
- human melanoma (1)
- hypersensitivity (1)
- hypothalamic gene expression (1)
- hypoxia (1)
- idiopathic fecal incontinence (1)
- imaging (1)
- immaturity (1)
- immundominant (1)
- immune check inhibitor (1)
- immune response (1)
- immunity (1)
- immunodominant (1)
- immunosuppression (1)
- immunotherapeutics (1)
- impedance spectroscopy (1)
- imperforate anus (1)
- in vitro model (1)
- in vivo (1)
- in-vitro fertilization (1)
- incisional abdominal wall hernia (1)
- induced obesity (1)
- infants born (1)
- inflammation-induced tissue demage (1)
- inflammatory cell model (1)
- inguinal hernia (1)
- inguinal lymph node dissection (1)
- insulin resistance (1)
- intercellular junctions (1)
- intestinal barrier (1)
- intestinal glucose (1)
- intestinal microbiota (1)
- intestinal organoids (1)
- intestine (1)
- intraabdominal abscess (1)
- intragastric balloon (1)
- intravascular ultrasound (IVUS) (1)
- intravenous glucose tolerance test (1)
- ionizing radiation (1)
- irinotecan (1)
- islet transplantation (1)
- isocaloric intake (1)
- isosteviol sodium (STVNA) (1)
- kappa-B (1)
- ketogenic dients (1)
- ketogenic diet (1)
- ketone bodies (1)
- kidney (1)
- kidneys (1)
- la antigens (1)
- laparoscopic appendectomy (1)
- laparoscopic course (1)
- laparoscopic right colectomy (1)
- laparoscopic skills (1)
- laparoscopy (1)
- late onset sepsis (1)
- learning curve (1)
- left hemicolectomy (1)
- leptin (1)
- leptin system (1)
- leukemia (1)
- level of evidence: IV (1)
- linea alba (1)
- lipoblastoma (1)
- lipodystrophy (1)
- liver resection (1)
- locally advanced disease (1)
- low molecular heparin (1)
- low-grade mucinous neoplasm (1)
- low-molecular heparin (1)
- low-risk intra-abdominal infections (1)
- lung resection (1)
- lymph node dissection (1)
- lymph nodes (1)
- lymphadenectomy (1)
- lymphomatoid papulosis (1)
- magnetic resonance imaging (1)
- maintain immune homeostasis (1)
- management (1)
- mass (1)
- mastocytosis (1)
- measles virus (1)
- medial patellofemoral ligament (1)
- meningitis (1)
- mesenchymal stem cells (1)
- mesh augmentation (1)
- mesh repair (1)
- metaanalysis (1)
- metabolic profile (1)
- metabolically unhealthy obesity (1)
- metabolism (1)
- metachronous (1)
- miRNA expression (1)
- mice (1)
- microbiota (1)
- mild hypothermia (1)
- minimally invasive (1)
- modified Sugarbaker technique (1)
- mold exposure (1)
- molecular diagnostics (1)
- monocyte subsets (1)
- monocytes (1)
- mortality rate (1)
- mucormycosis (1)
- mucosal healing (MH) (1)
- multimodal (1)
- myeloid (1)
- nab-paclitaxel (1)
- negative pressure wound therapy (1)
- neoadjuvant (1)
- neoadjuvant chemotherapy (1)
- neonatal immunology (1)
- neonatal meningitis (1)
- neonatal outcome (1)
- netrin-1 (1)
- neuroblastoma – diagnosis (1)
- neuroendocrine tumor (NET) (1)
- neuroinflammation (1)
- neuropathic pain (1)
- neurotrophic factors (1)
- noradrenaline (1)
- noradrenaline transporter (1)
- novel human cadaveric perfusion model (1)
- obesity surgery (1)
- octogenarians (1)
- octogenerians (1)
- older adult (1)
- oncogene-induced senescence (1)
- open appendectomy (1)
- open wound treatment (1)
- operative (1)
- oral anticoagulants (1)
- organoid (1)
- outcome (1)
- pancreas Islets (1)
- pancreatectomy (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic head cancer (1)
- parathyroid adenoma (1)
- parathyroid carcinoma (1)
- patella alta (1)
- patella dislocation (1)
- patella instability (1)
- pathway analysis (1)
- patient-derived organoid (PDOs) (1)
- patient-derived tumor organoid (PDTO) (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical cancer (1)
- pediatric adrenocortical tumor (1)
- pelvic trauma (1)
- pembrolizumab (1)
- pemphigus (1)
- penetrating ileitis (1)
- peptide analogs (1)
- peptide tyrosine tyrosine 3-36 (PYY3-36) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- perianal fistulas (1)
- perioperative antibiotic prophylaxis (1)
- perioperative chemotherapy (1)
- periphery-brain interactions (1)
- peritonitis (1)
- permeability (1)
- peroral endoscopic myotomy (1)
- phosphodiesterase-4 (1)
- phosphodiesterase-inhibitors (1)
- photon-counting computed tomography (CT) (1)
- pig or swine (1)
- platelet dysfunction (1)
- popliteal aneurysm (1)
- positron emission tomography imaging (1)
- post-mortem heart recovery (1)
- post-operative antibiotic treatment (1)
- posterior component separation (1)
- postoperative inflammation (1)
- preclinical research (1)
- preoperative localization (1)
- preterm birth (1)
- prevalence (1)
- primary hyperparathyroidism (1)
- primär ventrale Hernie (1)
- prognosis (1)
- prognostic factors (1)
- prospective studies (1)
- protein expression (1)
- protein kinase D2/PKD2/PRKD2 (1)
- protein synthesis (1)
- quality of life (1)
- radiotracer (1)
- reactivating p53 and inducing tumor apoptosis (RITA) (1)
- reactive oxygen (1)
- reactive oxygen species (1)
- real-time glucose monitoring (1)
- rectal cancer (1)
- rectal resection (1)
- recurrence survival (1)
- recurrent abdominal wall hernia (1)
- regeneration (1)
- regenerative medicine (1)
- regional recurrence (1)
- regionalization and organoids (1)
- registries (1)
- regulatory T cells (1)
- renal transplantation (1)
- repeat surgery (1)
- repeated surgery (1)
- reproductive medicine (1)
- resuscitation time (1)
- retromuscular mesh (1)
- retroperitoneal tumor (1)
- retrorectus mesh (1)
- retrospective study (1)
- reverse transcriptase-polymerase chain reaction (1)
- review (1)
- ribosome (1)
- risk factor (1)
- risk factors (1)
- robotic surgery (1)
- robotic surgical procedures (1)
- rolipram (1)
- rygb (1)
- sacral nerve stimulation (1)
- sacral neuromodulation (1)
- screening (1)
- seahorse (1)
- secondary skin closure (1)
- secretion (1)
- seminoma (1)
- septic (1)
- seroma (1)
- serotonin (1)
- serotonin transporter (1)
- shock (1)
- single-port appendectomy (1)
- sleeve gastrectomy (1)
- small bowel (1)
- small interferring RNA (1)
- small pixel effect (1)
- streptozotocin (1)
- super-obesity (1)
- superior (1)
- surgical (1)
- surgical and invasive medical procedures (1)
- surgical care (1)
- surgical complications (1)
- surgical intra-abdominal infections (1)
- surgical management (1)
- surgical oncology (1)
- surgical outcome (1)
- surgical procedures (1)
- surgical resection (1)
- surgical site infection (1)
- surgical site infections (1)
- surgical trauma room (1)
- surgical treatment (1)
- survival (1)
- survival analysis (1)
- sympathetic nervous system (1)
- systematic review (1)
- systemic and cutaneous CD30+ lymphoproliferations (1)
- systemic endotoxemia (1)
- teaching methods (1)
- technology (1)
- terminal ileitis (1)
- thermogenesis (1)
- thyroid gland (1)
- thyroiditis (1)
- tight junction (1)
- tight junction proteins (1)
- tissue (1)
- tolerance (1)
- total pancreatectomy (1)
- transanal endoscopic microsurgery (TEM) (1)
- transarterial chemoembolization (1)
- translation (1)
- translation initiation (1)
- transplant (1)
- transplantation (1)
- transstomal endoluminal vacuum therapy (1)
- transverse fascia (1)
- trauma centre (1)
- trauma management (1)
- trochlear dysplasia (1)
- trophic factors (1)
- tumor disease (1)
- tumor growth (1)
- type 2 diabetes (1)
- ultrahigh resolution (1)
- uncoupling protein 1 (1)
- urinary tract infections (1)
- urine (1)
- vascular type (1)
- vasculitis (1)
- ventral hernia model (1)
- visceral fat (1)
- vitamin D (1)
- volume (1)
- warfarin interruption (1)
- weight-gain (1)
- wound infection (1)
- xenogeneic transplantation (1)
- xenogenic transplantation (1)
- β-Hydroxybutyrate (1)
Institute
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (231) (remove)
Sonstige beteiligte Institutionen
Background
Anastomotic leakage (AL) is one of the most common and serious complications following visceral surgery. In recent years, endoluminal vacuum therapy has dramatically changed therapeutic options for AL, but its use has been limited to areas easily accessible by endoscope.
Case presentation
We describe the first use of endoluminal vacuum therapy in the small intestine employing a combined surgical and endoscopic “rendezvous technique” in which the surgeon assists the endoscopic placement of an endoluminal vacuum therapy sponge in the jejunum by means of a pullback string. This technique led to a completely closed AL after 27 days and 7 changes of the endosponge.
Conclusion
The combined surgical and endoscopic rendezvous technique can be useful in cases of otherwise difficult endosponge placement.
Purpose
This study investigates the redislocation rate and functional outcome at a minimum follow-up of five years after medial patellofemoral ligament (MPFL) reconstruction with soft tissue patellar fixation for patella instability.
Methods
Patients were retrospectively identified and knees were evaluated for trochlea dysplasia according to Dejour, for presence of patella alta and for presence of cartilage lesion at surgery. At a minimum follow-up of five years, information about an incident of redislocation was obtained. Kujala, Lysholm, and Tegner questionnaires as well as range of motion were used to measure functional outcome.
Results
Eighty-nine knees were included. Follow-up rate for redislocation was 79.8% and for functional outcome 58.4%. After a mean follow-up of 5.8 years, the redislocation rate was 5.6%. There was significant improvement of the Kujala score (68.8 to 88.2, p = 0.000) and of the Lysholm score (71.3 to 88.4, p = 0.000). Range of motion at follow-up was 149.0° (115–165). 77.5% of the knees had patella alta and 52.9% trochlear dysplasia types B, C, or D. Patellar cartilage legions were present in 54.2%. Redislocations occurred in knees with trochlear dysplasia type C in combination with patella alta.
Conclusion
MPFL reconstruction with soft tissue patellar fixation leads to significant improvement of knee function and low midterm redislocation rate. Patients with high-grade trochlear dysplasia should be considered for additional osseous correction.
Background
The vascular type represents a very rare, yet the clinically most fatal entity of Ehlers-Danlos syndrome (EDS). Patients are often admitted due to arterial bleedings and the friable tissue and the altered coagulation contribute to the challenge in treatment strategies. Until now there is little information about clotting characteristics that might influence hemostasis decisively and eventually worsen emergency situations.
Results
22 vascular type EDS patients were studied for hemoglobin, platelet volume and count, Quick and activated partial thromboplastin time, fibrinogen, factor XIII, von Willebrand disease, vitamin D and platelet aggregation by modern standard laboratory methods. Results show a high prevalence of over 50 % for platelet aggregation disorders in vascular type EDS patients, especially for collagen and epinephrine induced tests, whereas the plasmatic cascade did not show any alterations. Additionally, more than half of the tested subjects showed low vitamin D serum levels, which might additionally affect vascular wall integrity.
Conclusion
The presented data underline the importance of detailed laboratory screening methods in vascular type EDS patients in order to allow for targeted application of platelet-interacting substances that might be of decisive benefit in the emergency setting.
Background
Valid indicators are required to measure surgical quality. These ideally should be sensitive and selective while being easy to understand and adjust. We propose here the MTL30 quality indicator which takes into account 30-day mortality, transfer within 30 days, and a length of stay of 30 days as composite markers of an uneventful operative/postoperative course.
Methods
Patients documented in the StuDoQ|Colon and StuDoQ|Rectal carcinoma register of the German Society for General and Visceral Surgery (DGAV) were analyzed with regard to the effects of patient and tumor-related risk factors as well as postoperative complications on the MTL30.
Results
In univariate analysis, the MTL30 correlated significantly with patient and tumor-related risk factors such as ASA score (p<0.001), age (p<0.001), or UICC stage (p<0.001). There was a high sensitivity for the postoperative occurrence of complications such as re-operations (p<0.001) or subsequent bleeding (p<0.001), as well as a significant correlation with the CDC classification (p<0.001). In multivariate analysis, patient-related risk factors and postoperative complications significantly increased the odds ratio for a positive MTL30. A negative MTL30 showed a high specify for an uneventful operative and postoperative course.
Conclusion
The MTL30 is a valid indicator of colorectal surgical quality.
Ureaplasma species (spp.) are considered commensals of the adult genitourinary tract, but have been associated with chorioamnionitis, preterm birth, and invasive infections in neonates, including meningitis. Data on mechanisms involved in Ureaplasma-driven neuroinflammation are scarce. The present study addressed brain inflammatory responses in preterm lambs exposed to Ureaplasma parvum (UP) in utero. 7 days after intra-amniotic injection of UP (n = 10) or saline (n = 11), lambs were surgically delivered at gestational day 128–129. Expression of inflammatory markers was assessed in different brain regions using qRT-PCR and in cerebrospinal fluid (CSF) by multiplex immunoassay. CSF was analyzed for UP presence using ureB-based real-time PCR, and MRI scans documented cerebral white matter area and cortical folding. Cerebral tissue levels of atypical chemokine receptor (ACKR) 3, caspases 1-like, 2, 7, and C–X–C chemokine receptor (CXCR) 4 mRNA, as well as CSF interleukin-8 protein concentrations were significantly increased in UP-exposed lambs. UP presence in CSF was confirmed in one animal. Cortical folding and white matter area did not differ among groups. The present study confirms a role of caspases and the transmembrane receptors ACKR3 and CXCR4 in Ureaplasma-driven neuroinflammation. Enhanced caspase 1-like, 2, and 7 expression may reflect cell death. Increased ACKR3 and CXCR4 expression has been associated with inflammatory central nervous system (CNS) diseases and impaired blood–brain barrier function. According to these data and previous in vitro findings from our group, we speculate that Ureaplasma-induced caspase and receptor responses affect CNS barrier properties and thus facilitate neuroinflammation.
Ureaplasma species are common colonizers of the adult genitourinary tract and often considered as low-virulence commensals. Intraamniotic Ureaplasma infections, however, facilitate chorioamnionitis and preterm birth, and cases of Ureaplasma-induced neonatal sepsis, pneumonia, and meningitis raise a growing awareness of their clinical relevance. In vitro studies are scarce but demonstrate distinct Ureaplasma-driven impacts on immune mechanisms. The current study addressed cytokine and chemokine responses upon exposure of native or lipopolysaccharide (LPS) co-stimulated human brain microvascular endothelial cells (HBMEC) to Ureaplasma urealyticum or U. parvum, using qRT-PCR, RNA sequencing, multi-analyte immunoassay, and flow cytometry. Ureaplasma exposure in native HBMEC reduced monocyte chemoattractant protein (MCP)-3 mRNA expression (p < 0.01, vs. broth). In co-stimulated HBMEC, Ureaplasma spp. attenuated LPS-evoked mRNA responses for C-X-C chemokine ligand 5, MCP-1, and MCP-3 (p < 0.05, vs. LPS) and mitigated LPS-driven interleukin (IL)-1α protein secretion, as well as IL-8 mRNA and protein responses (p < 0.05). Furthermore, Ureaplasma isolates increased C-X-C chemokine receptor 4 mRNA levels in native and LPS co-stimulated HBMEC (p < 0.05). The presented results may imply immunomodulatory capacities of Ureaplasma spp. which may ultimately promote chronic colonization and long-term neuroinflammation.
Purpose: In hepatocellular carcinoma patients with large or multinodal tumors, where curative treatment options are not feasible, transarterial therapies play a major role. Transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) is a promising new approach due to higher intratumoral and lower systemic concentration of the chemotherapeutic agent compared to conventional TACE (cTACE).
Patients and methods: In a retrospective analysis, 32 patients with hepatocellular carcinoma who received either DEB or a cTACE were compared regarding survival time, disease recurrence, and side effects such as pain and fever.
Results: No significant differences could be detected between the cTACE and DEB-TACE groups with regard to mean hospital stay, appearance of postinterventional fever, or 30-day mortality. However, the application of intravenous analgesics as postinterventional pain medication was needed more often in patients treated with DEB-TACE (57.1% vs 12.5%, P=0.0281). The overall median survival after the initial procedure was 10.8 months in the cTACE group and 9.2 months in the DEB-TACE group, showing no significant difference.
Conclusion: No survival benefit for patients treated with either DEB-TACE or cTACE was observed. Surprisingly, a higher rate of postinterventional pain could be detected after DEB-TACE.
Background
Combination therapies of anorectic gut hormones partially mimic the beneficial effects of bariatric surgery. Thus far, the effects of a combined chronic systemic administration of Glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) have not been directly compared to Roux-en-Y gastric bypass (RYGB) in a standardized experimental setting.
Methods
High-fat diet (HFD)-induced obese male Wistar rats were randomized into six treatment groups: (1) RYGB, (2) sham-operation (shams), (3) liraglutide, (4) PYY\(_{3-36}\), (5) PYY\(_{3-36}\)+liraglutide (6), saline. Animals were kept on a free choice high- and low-fat diet. Food intake, preference, and body weight were measured daily for 4 weeks. Open field (OP) and elevated plus maze (EPM) tests were performed.
Results
RYGB reduced food intake and achieved sustained weight loss. Combined PYY\(_{3-36}\)+liraglutide treatment led to similar and plateaued weight loss compared to RYGB. Combined PYY\(_{3-36}\)+liraglutide treatment was superior to PYY\(_{3-36}\) (p ≤ 0.0001) and liraglutide (p ≤ 0.05 or p ≤ 0.01) mono-therapy. PYY\(_{3-36}\)+liraglutide treatment and RYGB also reduced overall food intake and (less pronounced) high-fat preference compared to controls. The animals showed no signs of abnormal behavior in OF or EPM.
Conclusions
Liraglutide and PYY\(_{3-36}\) combination therapy vastly mimics reduced food intake, food choice and weight reducing benefits of RYGB.
Toll like receptor (TLR) signaling has been suggested to play an important role in the inflammatory microenvironment of solid tumors and through this inflammation-mediated tumor growth. Here, we studied the role of tumor cells in their process of self-maintaining TLR expression independent of inflammatory cells and cytokine milieu for autoregulative tumor growth signaling in pancreatic cancer. We analyzed the expression of TLR2, -4, and -9 in primary human cancers and their impact on tumor growth via induced activation in several established pancreatic cancers. TLR-stimulated pancreatic cancer cells were specifically investigated for activated signaling pathways of VEGF/PDGF and anti-apoptotic Bcl-xL expression as well as tumor cell growth. The primary pancreatic cancers and cell lines expressed TLR2, -4, and -9. TLR-specific stimulation resulted in activated MAP-kinase signaling, most likely via autoregulative stimulation of demonstrated TLR-induced VEGF and PDGF expression. Moreover, TLR activation prompted the expression of Bcl-xL and has been demonstrated for the first time to induce tumor cell proliferation in pancreatic cancer. These findings strongly suggest that pancreatic cancer cells use specific Toll like receptor signaling to promote tumor cell proliferation and emphasize the particular role of TLR2, -4, and -9 in this autoregulative process of tumor cell activation and proliferation in pancreatic cancer.
Background
Reliable central venous access (CVC) is essential for hematology–oncology patients since frequent puncture of peripheral veins—e.g., for chemotherapy, antibiotic administration, repeated blood sampling, and monitoring—can cause unacceptable pain and psychological trauma, as well as severe side effects in cases of extravasation of chemotherapy drugs. However, CVC lines still carry major risk factors, including thrombosis, infection (e.g., entry site, tunnel, and luminal infections), and catheter dislocation, leakage, or breakage.
Methods
Here we performed a retrospective database analysis to determine the incidence of CVC-associated thrombosis in a single-center cohort of 448 pediatric oncologic patients, and to analyze whether any subgroup of patients was at increased risk and thus might benefit from prophylactic anticoagulation.
Results
Of the 448 patients, 269 consecutive patients received a CVC, and 55 of these 269 patients (20%) also had a thrombosis. Of these 55 patients, 43 had at least one CVC-associated thrombosis (total number of CVC-associated thrombosis: n = 52). Among all patients, the median duration of CVC exposure was 464 days. Regarding exposure time, no significant difference was found between patients with and without CVC-associated thrombosis. Subclavia catheters and advanced tumor stages seem to be the main risk factors for the development of CVC-associated thrombosis, whereas pharmacologic prophylaxis did not seem to have a relevant impact on the rate of thrombosis.
Conclusions
We conclude that pediatric surgeons and oncologists should pay close attention to ensuring optimal and accurate CVC placement, as this appears the most effective tool to minimize CVC-associated complications.
Melanoma and Merkel cell carcinoma (MCC) are highly aggressive cancers of the skin that frequently escape immune recognition and acquire resistance to chemotherapeutic agents, which poses a major obstacle to successful cancer treatment. Recently, a new class of therapeutics targeting the programmed cell death-1 (PD-1) immune checkpoint receptor has shown remarkable efficacy in the treatment of both cancers. Blockade of PD-1 on T cells activates cancer-specific immune responses that can mediate tumor regression. The data presented in this Ph.D. thesis demonstrates that PD-1 is also expressed by subsets of cancer cells in melanoma and MCC. Moreover, this work identifies PD-1 as a novel tumor cell-intrinsic growth receptor, even in the absence of T cell immunity. PD-1 is expressed by tumorigenic cell subsets in melanoma patient samples and established human and murine cell lines that also co-express ABCB5, a marker of immunoregulatory tumor- initiating cells in melanoma. Consistently, melanoma-expressed PD-1 downmodulates T effector cell functions and increases the intratumoral frequency of tolerogenic myeloid- derived suppressor cells. PD-1 inhibition on melanoma cells by RNA interference, blocking antibodies, or mutagenesis of melanoma-PD-1 signaling motifs suppresses tumor growth in immunocompetent, immunocompromised, and PD-1-deficient tumor graft recipient mice. Conversely, melanoma-specific PD-1 overexpression enhances tumorigenicity, including in mice lacking adaptive immunity. Engagement of melanoma- PD-1 by its ligand PD-L1 promotes tumor growth, whereas melanoma-PD-L1 inhibition or knockout of host-PD-L1 attenuates growth of PD-1-positive melanomas. Mechanistically, the melanoma-PD-1 receptor activates mTOR signaling mediators, including ribosomal protein S6. In a proof-of-concept study, tumoral expression of phospho-S6 in pretreatment tumor biopsies correlated with clinical responses to anti-PD-1 therapy in melanoma patients. In MCC, PD-1 is similarly co-expressed by ABCB5+ cancer cell subsets in clinical tumor specimens and established human cell lines. ABCB5 renders MCC cells resistant to the standard-of-care chemotherapeutic agents, carboplatin and etoposide. Antibody-mediated ABCB5 blockade reverses chemotherapy resistance and inhibits tumor xenograft growth by enhancing chemotherapy-induced tumor cell killing. Furthermore, engagement of MCC-expressed PD-1 by its ligands, PD-L1 and PD-L2, promotes proliferation and activates MCC-intrinsic mTOR signaling. Consistently, antibody- mediated PD-1 blockade inhibits MCC tumor xenograft growth and phosphorylation of mTOR effectors in immunocompromised mice. In summary, these findings identify cancer cell-intrinsic functions of the PD-1 pathway in tumorigenesis and suggest that blocking melanoma- and MCC-expressed PD-1 might contribute to the striking clinical efficacy of anti-PD-1 therapy. Additionally, these results establish ABCB5 as a previously unrecognized chemoresistance mechanism in MCC.
Crohn's disease (CD) represents a heterogeneous and complex disease with no curative therapeutic option available to date. Current therapy is mainly antibody-based focusing on the immune system while other treatment alternatives such as surgery are considered to be “last options”. However, medical therapy for CD results in mild to severe side effects in a relevant amount of patients and some patients do not respond to the medication. Following that, quality of life is often significantly reduced in this patient cohort, thus, therapeutic alternatives are urgently needed. Updated evidence has revealed that surgery such as ileocecal resection (ICR) might be a potential therapeutic option in case of localized terminal ileitis since resection at early time points improves quality of life and significantly reduces the postoperative need for immunosuppressive medication with low rates of morbidity. In addition, new surgical approaches such as Kono-S anastomosis or inclusion of the mesentery result in significantly reduced rates of disease recurrence and reoperation. Based on the new evidence, the goal of this review is to provide an update on the role of surgery as a reasonable alternative to medical therapy in the interdisciplinary treatment of patients with CD.
Familial gastrointestinal stromal tumors (GIST) are dominant genetic disorders that are caused by germline mutations of the type III receptor tyrosine kinase KIT. While sporadic mutations are frequently found in mastocytosis and GISTs, germline mutations of KIT have only been described in 39 families until now. We detected a novel germline mutation of KIT in exon 11 (p.Lys-558-Asn; K558N) in a patient from a kindred with several GISTs harboring different secondary somatic KIT mutations. Structural analysis suggests that the primary germline mutation alone is not sufficient to release the autoinhibitory region of KIT located in the transmembrane domain. Instead, the KIT kinase module becomes constitutively activated when K558N combines with different secondary somatic mutations. The identical germline mutation in combination with an additional somatic KIT mutation was detected in a second patient of the kindred with seminoma while a third patient within the family had a cutaneous mastocytosis. These findings suggest that the K558N mutation interferes with the juxtamembranous part of KIT, since seminoma and mastocystosis are usually not associated with exon 11 mutations.
To decrease immunogenicity of the rat kidney, grafts were perfused with an anti-MHC class li monoclonal antibody (mAb ). How effectively this procedure blocked dass li-positive cells, which were mainly dendritic in appearance, was checked by immunostaining renal sections after perfusion and comparing them with in vitro stained sections. Optimum conditions were applied for graft pretreatment before transplantation. This procedure prolonged graft survival, though not satisfactorily from the biological point ofview (9.6 ± 0.8 versus 7.7 ± 0.5 days in the control group; P < 0.02). The dendritic cells were not killed but blocked. Several hours after transplantation, the mAb dissociated from these dass li-positive cells. It was also shown that donor cells migrate into the recipient's spieen early after transplantation. The number of these cells was smaller when the transplanted organ was perfused with the mAb. Further studies are suggested to deplete the graft of donor dendritic cells more adequately. They should also combine graft perfusion with antidass II mAb and recipient immunosuppression at reduced doses.
Background
40–50% of patients with colorectal cancer (CRC) will develop liver metastases (CRLM) during the course of the disease. One third of these patients will additionally develop pulmonary metastases.
Methods
137 consecutive patients with CRLM, were analyzed regarding survival data, clinical, histological data and treatment. Results were stratified according to the occurrence of pulmonary metastases and metastases resection.
Results
39% of all patients with liver resection due to CRLM developed additional lung metastases. 44% of these patients underwent subsequent pulmonary resection. Patients undergoing pulmonary metastasectomy showed a significantly better five-year survival compared to patients not qualified for curative resection (5-year survival 71.2% vs. 28.0%; p = 0.001). Interestingly, the 5-year survival of these patients was even superior to all patients with CRLM, who did not develop pulmonary metastases (77.5% vs. 63.5%; p = 0.015). Patients, whose pulmonary metastases were not resected, were more likely to redevelop liver metastases (50.0% vs 78.6%; p = 0.034). However, the rate of distant metastases did not differ between both groups (54.5 vs.53.6; p = 0.945).
Conclusion
The occurrence of colorectal lung metastases after curative liver resection does not impact patient survival if pulmonary metastasectomy is feasible. Those patients clearly benefit from repeated resections of the liver and the lung metastases.